Aprea Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

APRE$0.50-3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

Exhibit Index


Exhibit
Number		Description of Document

4.1		Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

4.2		Form of Tranche A Warrant (incorporated herein by reference to Exhibit 4.2 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

4.3		Form of Tranche B Warrant (incorporated herein by reference to Exhibit 4.3 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

10.1		Form of Securities Purchase Agreement, dated as of March 11, 2024, by and between Aprea Therapeutics, Inc. and the purchasers named therein (incorporated herein by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

10.2		Form of Registration Rights Agreement, dated as of March 11, 2024, by and between Aprea Therapeutics and the purchasers (incorporated herein by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

10.3		Placement Agency Agreement, dated as of March 11, 2024, by and between Aprea Therapeutics, Inc. and Maxim Group LLC (incorporated herein by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the SEC on March 12, 2024).

10.4		Employment Agreement, effective as of May 1, 2024, by and between Aprea Therapeutics, Inc. and Nadeem Q. Mirza, M.D., M.P.H.

10.5		Aprea Therapeutics, Inc. Inducement Stock Option Agreement, dated May 1, 2024, by and between Aprea Therapeutics, Inc. and Nadeem Q. Mirza, M.D., M.P.H.

10.6		Aprea Therapeutics, Inc. Inducement Restricted Stock Unit Award Agreement, dated May 1, 2024, by and between Aprea Therapeutics, Inc. and Nadeem Q. Mirza, M.D., M.P.H.

31.1		Certification of the Registrant’s Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Registrant’s Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of the Registrant’s Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of the Registrant’s Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		XBRL Schema Document.

101.CAL		XBRL Calculation Linkbase Document.


Exhibit
Number		Description of Document

101.DEF		XBRL Definition Linkbase Document.

101.LAB		XBRL Label Linkbase Document.

101.PRE		XBRL Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

*	The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: May 14, 2024	Aprea Therapeutics, Inc.

	By:	/s/ Oren Gilad
		Oren Gilad, Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

Date: May 14, 2024

	By:	/s/ John P. Hamill
		John P. Hamill
		Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.